Matinas BioPharma Files 8-K: Officer/Director Changes & Financials
Ticker: MTNB · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1582554
| Field | Detail |
|---|---|
| Company | Matinas Biopharma Holdings, Inc. (MTNB) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $299,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, financials
TL;DR
Matinas BioPharma 8-K: Leadership changes and financial updates filed Dec 12, 2025.
AI Summary
Matinas BioPharma Holdings, Inc. filed an 8-K on December 12, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directors or officers can signal internal shifts that may affect company strategy or stability.
Key Players & Entities
- Matinas BioPharma Holdings, Inc. (company) — Registrant
- December 12, 2025 (date) — Date of earliest event reported
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates reporting on the departure of directors or certain officers, election of directors, and appointment of certain officers.
What other information is included in this 8-K filing?
The filing also includes information on compensatory arrangements of certain officers and financial statements and exhibits.
When was this 8-K report filed?
The report was filed on December 12, 2025.
What is the principal executive office address for Matinas BioPharma Holdings, Inc.?
The principal executive offices are located at 1545 Route 206 South, Suite 302, Bedminster, New Jersey 07921.
What is the company's state of incorporation and IRS Employer ID Number?
The company is incorporated in Delaware and its IRS Employer ID Number is 46-3011414.
Filing Stats: 894 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2025-12-12 17:00:34
Key Financial Figures
- $299,000 — such Change in Control occurs, or (ii) $299,000 (the "Retention Bonus"). The Amendmen
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 29KB
- 0001493152-25-027529.txt ( ) — 248KB
- mtnb-20251212.xsd (EX-101.SCH) — 3KB
- mtnb-20251212_lab.xml (EX-101.LAB) — 34KB
- mtnb-20251212_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: December 12, 2025 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer